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Abstract
Streptococcus agalactiae is a well-known pathogen for neonates and immunocompromized adults. Beyond the neonatal
period, S. agalactiae is rarely found in the respiratory tract. During 2002–2008 we noticed S. agalactiae in respiratory
secretions of 30/185 (16%) of cystic fibrosis (CF) patients. The median age of these patients was 3–6 years older than the
median age CF patients not harboring S. agalactiae. To analyze, if the S. agalactiae isolates from CF patients were clonal,
further characterization of the strains was achieved by capsular serotyping, surface protein determination and multilocus
sequence typing (MLST). We found a variety of sequence types (ST) among the isolates, which did not substantially differ
from the MLST patterns of colonizing strains from Germany. However serotype III, which is often seen in colonizing strains
and invasive infections was rare among CF patients. The emergence of S. agalactiae in the respiratory tract of CF patients
may represent the adaptation to a novel host environment, supported by the altered surfactant composition in older CF
patients.
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Introduction
Streptococcus agalactiae (group B streptococci, GBS) is an important
human pathogen causing invasive disease in neonates and
immunocompromized adult patients. While the microorganism
is still the major cause of invasive bacterial infections in newborns,
cases among newborns declined during the last years due to
effective peripartal antibiotic prophylaxis. Nowadays over 80% of
invasive infections are observed in patients older than 18 years and
invasive disease in older patients appears to become more
prevalent. Interestingly in the years 2003, 2004 and 2005 more
adult patients died following invasive S. agalactiae infections than
invasive S. pyogenes disease (http://www.cdc.gov/ncidod/dbmd/
abcs/survreports/gbs05.pdf). These data suggest that the epide-
miology of S. agalactiae is changing and that the bacteria are
adapting to novel environments within the human host.
In contrast to closely related bacterial species like Streptococcus
pyogenes, S. agalactiae is only rarely seen as a colonizer in respiratory
secretions from pediatric patients beyond the neonatal period [1,2].
Investigations concerning the presence of S. agalactiae in the
respiratory tract of cystic fibrosis patients have to our knowledge
not been published. Microorganisms most frequently seen in the
respiratory secretions of patients suffering from cystic fibrosis (CF)
are Pseudomonas aeruginosa, Staphylococcus aureus and Haemophilus
influenzae [3,4]. The occurrence of beta hemolytic streptococci is
rarely reported in CF patients. One study recovered 6 isolates from
the analysis of 258 CF respiratory tract specimens [5]. A more
recent comprehensive investigation of 465 CF patients for
colonizing gram positive microorganisms isolated S. pyogenes in 4
samples butdidnotfind a single patientcolonized byS.agalactiae[4].
Traditional subtyping methods for S. agalactiae rely on antibody
determination of the capsular serotypes and surface protein
structures. During the last years the repertoire of subtyping
methods for S. agalactiae have been expanded by DNA sequence
based methods like multi locus sequence typing (MLST) [6]. The
technique has become one of the most powerful tools to
characterize bacterial populations. It offers major advantages in
comparison to older methods. The results are unambiguous, stable
and the profiles of strains can be easily compared between
different laboratories without the need to analyze strains of interest
in one experiment. Moreover the data are comparable via the
internet between different laboratories, which facilitates popula-
tion analyzes worldwide. During the last years hundreds of
invasive and colonizing S. agalactiae strains have been characterized
with this method und today more than 380 MLST sequence types
for S. agalactiae are recognized. Evolutionary relationships in the
population structure of S. agalactiae can be analyzed with the
eBURSTV3 program which identifies clonal complexes based on
variations in the allelic MLST profiles of analyzed strains and
allows a graphic representation of genetic relatedness [7].
The detection of S. agalactiae isolates in 16% of the patients from
a population of 185 CF patients during 2002–2008 was surprising
and to rule out a local outbreak, the molecular epidemiology of the
strains was investigated. Furthermore the CF strains were
compared to the general population structure of German S.
agalactiae strains. For this purpose, 72 colonizing strains that were
PLoS ONE | www.plosone.org 1 February 2009 | Volume 4 | Issue 2 | e4650collected during a recent German colonization study of healthy
adults [8] were characterized by MLST.
Materials and Methods
Processing of CF respiratory tract specimens
Respiratory specimens from CF patients were collected during
clinical visits between 2002 and 2008. Samples were sent in from
two different clinics spezialized on the treatment of CF patients in
the region of Mu ¨nster, Germany. Sputa were processed as follows:
500 ml sputum was mixed with 500 ml 0.5% acetylcystein (Merck),
vortexed, incubated for 30 min at 35uC and homogenized by
vortexing. 100 ml of the liquidified sputum was plated on
Columbia blood and Endo agar for semiquantitative analysis.
Primary cultures were performed on Columbia (Becton Dickinson,
Heidelberg, Germany) sheep blood (Oxoid, Wesel, Germany) agar
for Gram-positive cocci, on Endo agar (Merck, Darmstadt,
Germany) for Gram-negative rods for 48 h at 35uC and on
chocolate agar (Mast, Reinfeld, Germany) for Haemophilus influenzae
for 24–48 h at 35uC under 5% CO2. Additionally, specimens were
cultured in dextrose broth to enrich bacterial growth and streaked
on blood and Endo agar after 48 h. Species identification was
performed by respective standard procedures and the VITEK2
(bioMerieux, Marcy l’Etoile, France).
Molecular typing of capsular antigens and surface
proteins
Capsular serotypes of analyzed strains were determined by PCR
of cps genes for serotypes Ia, Ib, III, IV, V and VI and DNA
sequencing for serotype II strains was carried out as described by
Kong F, et al. [9]. To determine the surface proteins of the strains
a multiplex PCR reaction was carried out as described in [10]. For
strains that did not yield any results in the multiplex PCR reaction,
the PCR was repeated using the primer pairs specific for one
surface protein in a single reaction mixture.
Multi locus sequence typing
Multi locus sequence typing (MLST) of the S. agalactiae strains
from CF patients and the 72 colonizing isolates was carried out as
described by [6]. The colonizing strains were collected in a
previous study [8], they originated from either vaginal or rectal
specimens. Primers as listed in [6] were obtained from a
commercial supplier (Thermo Hybaid, Ulm, Germany). Genomic
bacterial DNA of S. agalactiae was isolated by using the QiaAmp
DNA kit (Qiagen, Hilden, Germany) as described by the
manufacturer. PCR conditions to amplify the adhP, pheS, atr, glnA,
sdhA, glcK and tkt genes were set as described previously [6].
Sequencing of the generated PCR products was performed on an
ABI Prism 310 Genetic Analyser (ABI Prism Biosystems,
Warrington, UK) according to the instructions of the manufac-
turer. For analysis of the obtained nucleotide sequences and
assignment of MLST profiles the following website: http://
pubmlst.org/sagalactiae/ was used. Burst analysis to reveal the
relationship of MLST sequence types and to analyze clonal
complexes was carried out with the eBURSTV3 version that is
accessible under: http://eburst.mlst.net.
Antimicrobial susceptibility determination
For all CF S. agalactiae isolates, minimal inhibitory concentra-
tions (MIC) of antibiotics were determined. The Merlin MICRO-
NAUT system was used to determine MIC values for penicillin,
ampicillin, cefuroxime, ceftriaxone, erythromycin, clarithromycin,
clindamycin, doxycycline and moxifloxacin. Standard susceptibil-
ity testing was performed after overnight culture on blood agar
plates as detailed in [11]. MIC values for gentamicin, vancomycin,
rifampicin and levofloxacin were determined by E-test in
accordance with the manufacturer’s instructions (AB-Biodisk,
Solna Sweden).
Results
Clinical characteristics of S. agalactiae positive CF
patients
From 16 of the 30 S. agalactiae positive CF patients bacterial
isolates for analysis by MLST were available. All of the strains
displayed a typical S. agalactiae phenotype. From the 16 patients a
total of 29 S. agalactiae strains were recovered and analyzed.
Among these strains there were 19 unique S. agalactiae strains and
10 strains that turned out to be duplicates of previous isolates in
patients that were colonized for a longer period of time. Clinical
characteristics of these patients are shown in Table 1. The female
to male ration among the patients was 50%. Only 1 patient of the
16 was younger than 10 years at the time S. agalactiae was first
detected. While the median age of the S. agalactiae positive CF
patients was 16,5 (range 10–22) and 22,5 (range 19–44)
respectively at the two different clincis at the end of 2008, the
median age of the general CF population not harboring S.
agalactiae, at this clinics was 13,6 (range 1,3–35,8) and 16,22 (range
0,7–50). To assess the potential clinical implications of S. agalactiae
in the respiratory tract of CF patients, we obtained the
information, if S. agalactiae isolation occurred during a routine
visit or during a visit due to an exacerbation of clinical symptoms.
For two of the patients it was not possible to gather this
information retrospectively. For the other patients, 24 clinical
visits were recorded in connection with positive S. agalactiae
isolation, 12 of these visits occurred due to an exacerbation of
symptoms, while the others were scheduled routine visits. In most
cases S. agalactiae was not the sole bacterial isolate from the sputum
samples. The concomitant pathogenic bacteria that were isolated
are listed in Table 1. Interestingly in 10 of 16 patients Staphylococcus
aureus was found, while only 4 patients harbored Pseudomonas
aeruginosa in their respiratory secretions in parallel to S. agalactiae.
Diabetes as a clinical presentation is not unusual in older CF
patients and S. agalactiae infections are more prevalent in diabetic
patients [12]. However among the CF patients with S. agalactiae
none had diabetes, when S. agalactiae was first isolated, even though
one patient became diabetic 4 years later.
MLST sequence types and burst analysis
Unequivocal MLST sequence types could be assigned to all of
the 19 CF strains and to all of the 72 colonizing strains that were
investigated in this study. Among the S. agalactiae strains from CF
patients ten different MLST sequence types were observed
(Table 2). This is a clear indication that we did not encounter
the situation of a local outbreak. To identify clonal complexes and
to reveal relationships among strains, the colonizing strains as well
as the S. agalactiae strains isolated from CF patients were subjected
to an analysis by the eBURSTV3 program. Most of the colonizing
strains (66%) and 13 of 19 CF isolates belonged to BURST group
1 (Table 2 and Table 3), which represents the biggest clonal
complex in the S. agalactiae population. Strains belonging to the
largest 3 of the so far recognized BURST groups of S. agalactiae
were present in the CF isolates as well as in the colonizing strains.
The pattern observed for the colonizing strains did not appear to
differ substantially from the pattern and clonal complexes that are
present in the S. agalactiae MLST database, even though some STs
were present only in colonizing or CF strains (Table 2 and
Table 3). A graphic representation of the data is shown in Fig. 1.
S. agalactiae in CF Patients
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In addition to the MLST analysis, all of the S. agalactiae strains
included in this study were characterized by capsular serotyping
and surface protein determination. Capsular serotypes could be
obtained for 17 of the 19 CF strains and all of the colonizing
strains. With the exception of fives strains (one CF and four
colonizing isolates) all of the strains also harbored a gene for one of
the following surface proteins: alpha C, Epsilon, Alp2/3 or Rib.
Association of surface protein antigens with MLST
sequence types
It has repeatedly been shown in epidemiologic investigations
that a specific capsular serotype of S. agalactiae can harbor different
surface protein antigens [10,13]. To investigate if this is also true
for MLST sequence types, we determined the surface antigen
profile of the analyzed strains and compared it with the respective
MLST sequence types. While the number of strains belonging to a
specific sequence type in this investigation was of course limited,
the association between sequence type and surface protein antigen
appeared to be closer for some sequence types than the association
between capsular serotype and surface proteins (Fig. 2). Among
the ST-10 isolates from CF patients (n=2) and the colonizing
strains (n=7), we detected three different serotypes (Ia, Ib and II)





























1 m 19 12 2 26/12 no E/R/E S. aureus
2 f 5 10 - - no unknown M. catarrhalis
3m 2 4 1 - - n oE H. influenzae
P. fluoreszenz
4f 3 9 1 - - n oE P. aeruginosa
5 f 13 1 3 23/1/10 no E/E/E/R S. aureus
E. coli
6 f 12 12 2 12/12 no R/R/R S. aureus
H. influenzae
7 m 17 88 2 88/88 no unknown S. aureus
8 f 15 88 1 88 no R/R S. aureus
E. cloacae
9 f 23 22 1 22 no R/E S. aureus
P. aeruginosa
10 m 13 1 - - no E S. aureus
1 1 f1 48 8- - n o E S. aureus
1 2 m 1 01 9- - n o R P. aeruginosa
atypical
Mycobacteria
1 3 m 2 01 9- - n o E P. aeruginosa
A. xylosoxidans
14 m 20 103 1 103 no R/R -
1 5 m 2 61 9- - n o E S. aureus
16 f 10 8 - - no R S. aureus
doi:10.1371/journal.pone.0004650.t001
Table 2. Molecular characterization of 19 unique S. agalactiae









1 1 3 V Alp2/3
1 VI alpha C
8 1 1 Ib alphaC
10 1 2 Ib alpha C
12 1 1 Ib alpha C
1 II alpha C
19 1 2 III Rib
1 NT* Rib
22 2 1 NT* alphaC
23 3 1 Ia Epsilon
26 5 1 V -
88 3 3 Ia Alp2/3
103 7 1 Ia alphaC
*Nontypable.
doi:10.1371/journal.pone.0004650.t002
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the 5 colonizing ST-28 strains we saw a bigger variety of surface
proteins than serotypes. Unfortunately the number of strains for
each ST was too low to allow statistical analysis.
Antimicrobal susceptibilty
CF patients are routinely and repeatedly treated with antibiotics
for their respiratory infections. To investigate, if increased
antibiotic resistance rates are observed in the CF patients that
harbor S. agalactiae in respiratory secretions, MIC (minimal
inhibitory concentration) values for a panel of different antibiotics
were determined and MIC50 and MIC90 data is shown in
Table 4. All of the strains were fully susceptible to penicillin. One
of the CF isolates displayed high level gentamicin resistance with a
MIC of $1024 mg/l. In addition a macrolide resistance was
observed in 4 of 19 unique strains and 11 of 19 strains were
resistant to doxycycline. Any further relevant resistance patterns
could not be detected.
Discussion
S. agalactiae is only rarely seen as a colonizing pathogen of the
respiratory tract of healthy pediatric patients beyond the neonatal
period. A comprehensive study screening for the presence of beta
hemolytic streptococci found group B streptococci in less than 3%
[1] of 184 healthy pediatric patients. But varying colonization rates
have been published for throat cultures of healthy patients. One
older US study showed a rate of 9% in a control group of students
with a mean age of 23 [14]. This study however employed
selective enrichment broth to optimize S. agalactiae recovery and
was not performed in CF patients, which harbor a multitude of
different bacteria in respiratory secretions. Studies on throat
colonization in Europe revealed much lower rates [1,2,15].
Investigations of the microbiological species isolated from the
respiratory tract of CF patients hardly ever reveal the presence of
S. agalactiae [4]. Therefore, we were surprised to detect S. agalactiae
in 16% in a population of 185 CF patients that were regularly
screened during 2002–2008 for the presence of potential
pathogens in their respiratory tract samples. Especially in view
of the fact, that the samples were processed on regular blood agar
plates, which grow a multitude of different organisms in CF
patients. The detection rate of S. agalactiae in swabs increases about
100% if selective media for the cultivation of S. agalactiae are used
[16]. Thus it is likely that the true isolation rate of S. agalactiae from
the CF patients would be much higher, if antibiotic supplemented
media that inhibit the growth of other pathogens were used for
cultivation. This question however, could only be answered by a
prospective investigation of respiratory tract samples from CF
patients with liquid enrichment broth that optimizes the detection
rate of S. agalactiae. Increased numbers of S. agalactiae infections
have also been linked to diabetes [12] and CF patients may
become diabetic during the course of their disease. But since none
of the CF patients was diabetic at the time S. agalactiae was first
isolated from their sputum, there is no indication that the high S.
agalactiae isolation rates are due to an altered sugar metabolism in
these patients.
S. agalactiae belongs to the group of beta hemolytic streptococci,
which have a high virulence potential. In newborns and especially
premature infants with reduced pulmonary surfactant it causes
pneumonia and is a well recognized respiratory pathogen [17].
Surfactant associated protein A (SP-A) is the most abundant
pulmonary surfactant protein [18] and its importance for S.
agalactiae infections has been demonstrated in animal models [19].
In SP-A deficient knock out mice the clearance of intratracheally
administered S. agalactiae is delayed. Interestingly the concentration
of SP-A can be reduced in brocheo alveolar lavage fluid from CF
patients [20,21]. Older children and adult CF patients show
consistently decreased levels of SP-A, in contrast to young children
with CF. In our investigation, only one of the CF patients was
younger than 10 years at the time S. agalactiae was first isolated
from the sputum. Moreover the median age of CF patients with S.
agalactiae isolates was 3 and 6 years older than the S. agalcatiae
negative CF patients from the respective clinic. A finding which
supports the hypothesis, that altered surfactant properties in this
age group could be responsible for the emergence of S. agalactiae in
the respiratory tract. It could also explain, why respiratory S.
agalactiae isolates have previously not been reported in CF patients.
Due to improved therapeutic regimens for CF patients in recent
years, more than 35% of CF patients are now older than 18 years.
Whereas in the 60’s the predicted mean survival was only about 10
years [22]. But since we did not investigate the SP-A levels of the
patients which harbor S. agalactiae, this is only a speculation that
may be the target of further investigations.
Table 3. Molecular characterization of 72 colonizing S.










1 1 6 V Alp2/3
21 1 I a -
6 1 1 Ib alpha C
7 1 1 Ia alpha C
8 1 7 Ib alpha C
10 1 2 Ia alpha C
1 Ib alpha C
4 II alpha C
12 1 2 Ib alpha C
4 II alpha C
17 2 9 III Rib
19 1 2 II Rib
7I I I R i b
1 III Alp2/3
1I I I -
1V R i b




28 1 2 II Alp2/3
2I I -
1 II alpha C
41 1 1 V Rib
196 1 1 IV Epsilon
314 4 1 Ia Epsilon
389 none 1 II Alp2/3
1I I I R i b
doi:10.1371/journal.pone.0004650.t003
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29 S. agalactiae strains from CF patients were collected and
analyzed by molecular subtyping. Among these strains 19 unique
isolates were found and 10 strains that were identical to previous
isolates (Table 1). The presence of many different sequence types
in the CF isolates (Table 2) shows that these strains are
heterogeneous. We found no indication for a spread of a single
S. agalactiae clone among the patients. Despite the limited number
of strains from CF patients that we had for analysis, it is striking to
see, that serotype III was rarely isolated in CF patients. This is in
contrast to other German studies, in which serotype III isolates
were most prevalent in invasive neonatal strains (65%) [23] as well
as in colonizing strains (28%), obtained from adult women [8].
Analysis of the distribution of surface proteins among the CF
strains revealed a similar pattern. As expected, the surface protein
Rib was present in the serotype III strains we analyzed. Especially
striking was the absence of any ST-17 strains in the samples from
the CF patients. ST-17 serotpye III strains have been described as
hypervirulent isolates in many different studies, and have a strong
association with neonatal invasive disease and meningitis [24,25].
In contrast to the total lack of ST-17 strains in CF patients, nine
isolates of 72 from the German colonizing strains were ST-17
strains (Table 3), representing the third most frequent ST, an
indication that ST-17 strains are present in considerable numbers
in the pool of colonizing strains.
MLST characterization of S. agalactiae isolates from Germany
has not been performed and published previously. Therefore in
addition to the MLST analysis of the CF strains, we determined
the MLST profiles of 72 colonizing S. agalactiae isolates, which
were collected recently, as a reference population [8]. The MLST
pattern we found in our collection of colonizing strains compares
well to the MLST profiles seen in colonizing strains from other
countries [24,25]. The great majority of the MLST sequence types
that we determined in the CF isolates, were also present in the
German colonizing strains, indicating that the respiratory CF
strains and the urogenital colonizing strains belong to the same
population. In order to correlate the MLST sequence types with
known molecular markers of S. agalactiae, the CF isolates as well as
the colonizing strains from the urogenital tract of healthy patients
were characterized by serotyping and surface protein determina-
Figure 1. Population structure of Streptococcus agalactiae: Depicted are the three major recognized burst groups of S. agalactiae.
Sequence types that vary by one allele in their MLST profiles (single locus variants) are arranged in circles around the primary founder sequence type.
The population structure diagram was created based on the S. agalactiae MLST database as found under: http://eburst.mlst.net. Sequence types
present in our collection of colonizing strains are depicted as closed circles, sequence types found in the S. agalactiae strains form CF patients are
shown as open squares. The major clonal complexes (CC) are indicated in the picture.
doi:10.1371/journal.pone.0004650.g001
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serotypes and surface protein antigens exists [13], a detailed
analysis of the association of MLST sequence types and surface
proteins has not been published. Since there are many more
MLST sequence types than recognized S. agalactiae serotypes, it
was not surprising to see, that for most of the sequence types, only
a single type of surface protein was found in our investigation.
However for sequence types with many isolates like ST -1, ST- 19,
ST-23 and ST-28, we were able to detect strains with varying
surface proteins. For selected sequence types, like ST-10 and ST-
12 the association between MLST profiles and surface proteins
appeared to be closer than the association between sequence type
and serotype (Tables 2 and 3). In ST-10 and ST-12 isolates,
different serotypes were detected in one MLST sequence type, but
all of the strains belonging to that specific sequence type harbored
the same surface protein (Table 2 and 3). This was however not
true for all of the sequence types that we found, since in ST-28
only serotype II was observed, but alpha C protein as well as
Alp2/3 were detected in these strains. Overall the number of
isolates we had for analysis is too small to reach any definite
conclusions about the association of sequence types and surface
protein antigens.
During the course of many years CF patients are repeatedly
treated with anitibiotics to limit respiratory infections. Under these
conditions exposure of bacterial strains to various antibiotics for a
prolonged time is quite common, in contrast to the pregnant and
Figure 2. A: Association between surface proteins and sequence types. For each sequence type found in either respiratory strains from CF patients
or colonizing strains, the number of isolates and the surface proteins of these strains are shown. Genes coding for alpha C, Epsilon, Rib or Alp2/3 were
detected in the vast majority of strains, only five isolates failed to generate a PCR product with the specific primers. B: Association between serotypes
and sequence types. For each sequence type found in either respiratory strains from CF patients or colonizing strains, the number of isolates and the
serotypes of these strains are shown.
doi:10.1371/journal.pone.0004650.g002
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presence of S. agalactiae colonization. For other bacterial pathogens
high levels of antibiotic resistance rates have been reported in CF
patients [26]. In our collection of S. agalactiae isolates from CF
patients we were also able to observe an unusual resistance
pattern. One of the strains exhibited a high level gentamicin
resistance. This type of resistance is not common in S. agalactiae but
has previously been reported [27,28] in a few isolates. Resistance
rates to macrolides were found to be 21%, which is comparable to
the macrolides resistance rates of recent studies for S. agalactiae
[29,30]. In these investigations rates between 11% and 38% were
published.
In conclusion, we report the detection of S. agalactiae in a
considerable proportion of respiratory samples of CF patients.
Detailed molecular analysis of the strains did not reveal a local
outbreak. S. agalactiae positive patients were several years older
than a reference population of CF patients, which is consistent
with the hypothesis, that an altered surfactant composition in this
age group supports S. agalactiae growth. A condition, which may
help the adaptation of S. agalactiae to a novel, not yet recognized
host environment.
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Table 4. Antimicrobial susceptibilities of S. agalactiae isolates
from cystic fibrosis patients.




Penicillin #0.0625 #0.0625 0/19
Ampicillin #0.125 #0.125 0/19
Cefuroxime #0.125 #0.125 0/19
Ceftriaxone #0.125 #0.125 0/19
Erythromycin 0.5 .8 4/19
Clarithromycin #0.0625 .8 4/19
Clindamycin 0.125 .8 3/19
Doxycyclin 4 8 11/19
Rifampicin 0.125 0.125 0/19
Gentamicin 48 64 1/19*
Levofloxacin 0.75 1 0/19
Moxifloxacin 0.25 0.25 0/19
Vancomycin 0.5 0.5 0/19
*Depicted is the number of high level ($512 mg/l) gentamicin resistant strains.
doi:10.1371/journal.pone.0004650.t004
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